Your child may be eligible to participate in a research project that will help increase our understanding of childhood rheumatic diseases. We value participation in research because it is an important way for to learn new things about what is best for kids like yours! We participate in both of the major research networks for the specialty of Pediatric Rheumatology, namely PRCSG and CARRA. Feel free to ask your doctor or contact our research coordinator for more information: Sara Kramer at (612) 301-1554 or email@example.com.
Congratulations to the following Pediatric Rheumatology staff members who received an award at the 5th Annual Quality Forum for their presentation of a poster titled: Improvement in Uveitis Screening Documentation for Patients with Juvenile Idiopathic Arthritis. Our fellow, Dr. Danielle Bullock, presented the poster but all the staff listed contributed to the work: Danielle Bullock, Bryce Binstadt, Betty Bishop, Colleen Correll, Denise Erlanson, Patricia Hobday, Sara Kramer, Mona Riskalla, Richard Vehe
Juvenile Arthritis Minnesota (JaMINN) Study
The Juvenile Arthritis Minnesota (JaMINN) study is designed to learn more about the environmental factors that trigger JIA onset and disease flare in children.
Childhood Arthritis and Rheumatology Research Alliance (CARRA)
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is a North American organization of pediatric rheumatologists who are committed to advancing the health and quality of life of children living with rheumatic disease and arthritis and who have joined together to answer critical clinical research questions.
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
This is a long-term observational registry designed to answer pressing questions about therapies used for pediatric rheumatic diseases, including safety questions.
The Pediatric Rheumatology Collaborative Study Group (PRCSG)
"The Pediatric Rheumatology Collaborative Study Group (PRCSG) was founded in 1973 and has over 150 members at over 90 academic clinical pediatric rheumatology centers in the United States, Canada, and Puerto Rico. The chief aim of the PRCSG is to conduct high quality clinical trails, of therapeutic agents, in children with rheumatic diseases."
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis
This is a long-term observational registry for patients who are less than 18 years old and taking abatacept (Orencia). It is designed to carefully monitor the safety and effectiveness of this therapy for JIA.
A Long-Term, Open-Label Follow-Up Study of CP-690,550 for Treatment of Juvenile Idiopathic Arthritis (JIA)
This is a long-term follow-up study of the safety and effectiveness of tofacitinib for people who have participated in an earlier study of tofacitinib.